PharmTech Drug Digest 11.20
News|Articles|June 7, 2016

SGS to Offer HDX–MS at West Chester Facility

The company plans to introduce HDX–MS in quarter three of 2016 at its West Chester, PA facility.

On June 6, 2016, SGS announced that it will be offering hydrogen deuterium exchange mass spectrometry (HDX–MS) capabilities at its West Chester, Pennsylvania facility. This new service, which is currently undergoing installation, will assist in the full characterization of biological molecules, including biosimilars, SGS said in a press statement.

According to SGS, HDX–MS relies on proteins being exposed to deuterium water at extremely low temperatures, whereby hydrogen atoms on the outside of a folded protein molecule exchange with the deuterium atoms in the water at equilibrium. By analyzing the peptides on which atoms have been exchanged, detailed information on the protein folding can be obtained.

The HDX–MS service is expected to be introduced in quarter three of 2016 at the West Chester facility. SGS said it expects the addition of HDX–MS to increase the array of services for higher order protein analysis at the site, including circular dichroism, analytical ultra-centrifugation, size exclusion chromatography with multi-angle laser light scattering, and Fourier transform infrared spectroscopy.

Source: SGS 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.